SB939 compound

11/01/2013 - "This study assessed the toxicities and pharmacokinetics of pracinostat and determined the RP2D in children with refractory solid tumors. "
01/01/2021 - "Being pan-inhibitor pracinostat targets various classical HDACs and has demonstrated antiproliferative properties in a series of cancer cell lines. "
12/15/2017 - "Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. "
11/01/2013 - "Pracinostat is reasonably well tolerated in children with refractory solid tumors. "
11/01/2013 - "Pediatric patients with refractory solid tumors were treated with oral pracinostat t.i.w. "

12/01/2022 - "Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia."
01/01/2019 - "Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study."
12/15/2017 - "Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines. "
01/01/2019 - "Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. "

01/01/2020 - "A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy."
12/15/2017 - "As an extension, 10 additional patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine. "
05/15/2017 - "Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes."

01/01/2019 - "These findings do not support continued development of pracinostat in myelofibrosis."
01/01/2019 - "Pracinostat, a pan-HDACi, has modest single-agent activity in myelofibrosis. "
01/01/2019 - "We conducted a single-institution, phase 2, investigator-initiated trial of ruxolitinib plus pracinostat (begun after 12 weeks of ruxolitinib) in 25 patients with myelofibrosis, of whom 20 received both agents. "
01/01/2019 - "A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis."
09/01/2012 - "Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis."

12/15/2017 - "The results of the current study demonstrate that pracinostat is safe, with modest single-agent activity in patients with hematological malignancies. "
12/15/2017 - "Given the higher preclinical sensitivity of hematologic malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, maximum tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematological malignancies. "
12/15/2017 - "Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies."